
    
      This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study.
      This study is designed to determine the short- and long-term efficacy of reloxaliase in terms
      of reducing urinary oxalate excretion and clinical benefits compared to placebo.
    
  